References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26742998; PMID:26742998; http://dx.doi.org/10.3322/caac.21332
- Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH. Cell surface protein glycosylation in cancer. Proteomics 2014 [cited 2014 Oct 20]; 14:525-46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24339177; PMID:24339177; http://dx.doi.org/10.1002/pmic.201300387
- Julien S, Videira PA, Delannoy P. Sialyl-tn in cancer: (how) did we miss the target? Biomolecules 2012 [cited 2013 Jan 28]; 2:435-66. Available from: http://www.mdpi.com/2218-273X/2/4/435/; PMID:24970145; http://dx.doi.org/10.3390/biom2040435
- Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol 2015; 10:473-510. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25621663; PMID:25621663; http://dx.doi.org/10.1146/annurev-pathol-012414-040438
- Hofmann BT, Schlüter L, Lange P, Mercanoglu B, Ewald F, Fölster A, Picksak A-S, Harder S, El Gammal AT, Grupp K, et al. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer. Mol Cancer 2015; 14:109. Available from: http://www.molecular-cancer.com/content/14/1/109; PMID:26021314; http://dx.doi.org/10.1186/s12943-015-0386-1
- Pinho S, Marcos NT, Ferreira B, Carvalho AS, Oliveira MJ, Santos-Silva F, Harduin-Lepers A, Reis CA. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett 2007 [cited 2013 Jun 24]; 249:157-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16965854; PMID:16965854; http://dx.doi.org/10.1016/j.canlet.2006.08.010
- Ozaki H, Matsuzaki H, Ando H, Kaji H, Nakanishi H, Ikehara Y, Narimatsu H. Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clin Exp Metastasis 2012 [cited 2013 Sep 19]; 29:229-38. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3275730&tool=pmcentrez&rendertype=abstract; PMID:22228572; http://dx.doi.org/10.1007/s10585-011-9445-1
- Julien S, Lagadec C, Krzewinski-Recchi M-A, Courtand G, Le Bourhis X, Delannoy P. Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Res Treat 2005; 90:77-84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15770530; PMID:15770530; http://dx.doi.org/10.1007/s10549-004-3137-3
- Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, Gouyer V, Huet G, Le Bourhis X, Delannoy P. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J 2001; 18:883-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12820722; PMID:12820722; http://dx.doi.org/10.1023/A:1022200525695
- Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol 2014 [cited 2014 Mar 6]; 4:28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24592356; PMID:24592356; http://dx.doi.org/10.3389/fonc.2014.00028
- Padler-Karavani V. Aiming at the sweet side of cancer: aberrant glycosylation as possible target for personalized-medicine. Cancer Lett 2014 [cited 2013 Oct 24]; 352:102-12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24141190; PMID:24141190; http://dx.doi.org/10.1016/j.canlet.2013.10.005
- Andergassen U, Liesche F, Kölbl AC, Ilmer M, Hutter S, Friese K, Jeschke U. Glycosyltransferases as markers for early Tumorigenesis. Biomed Res Int 2015; 2015:792672. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26161413; PMID:26161413; http://dx.doi.org/10.1155/2015/792672
- Ju T, Wang Y, Aryal RP, Lehoux SD, Ding X, Kudelka MR, Cutler C, Zeng J, Wang J, Sun X, et al. Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteomics Clin Appl 2013; 7:618-31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23857728; PMID:23857728; http://dx.doi.org/10.1002/prca.201300024
- Loureiro LR, Carrascal MA, Barbas A, Ramalho JS, Novo C, Delannoy P, Videira PA. Challenges in antibody development against Tn and Sialyl-Tn Antigens. Biomolecules 2015 [cited 2015 Dec 10]; 5:1783-809. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4598775&tool=pmcentrez&rendertype=abstract; PMID:26270678; http://dx.doi.org/10.3390/biom5031783
- Beatson R, Maurstad G, Picco G, Arulappu A, Coleman J, Wandell HH, Clausen H, Mandel U, Taylor-Papadimitriou J, Sletmoen M, et al. The breast cancer-associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-Type Lectin MGL. PLoS One 2015; 10:e0125994. Available from: http://dx.plos.org/10.1371/journal.pone.0125994; PMID:25951175; http://dx.doi.org/10.1371/journal.pone.0125994
- Carrascal MA, Severino PF, Guadalupe Cabral M, Silva M, Ferreira JA, Calais F, Quinto H, Pen C, Ligeiro D, Santos LL, Dall'olio F VP. Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol Oncol 2014; 8(3):753-65: S1574-7891-7; PMID:24656965; http://dx.doi.org/10.1016/j.molonc.2014.02.008
- Julien S, Picco G, Sewell R, Vercoutter-Edouart A-S, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer 2009 [cited 2013 Jan 28]; 100:1746-54. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2695689&tool=pmcentrez&rendertype=abstract; PMID:19436292; http://dx.doi.org/10.1038/sj.bjc.6605083
- Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011 [cited 2013 Feb 22]; 16:1092-100. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3228158&tool=pmcentrez&rendertype=abstract; PMID:21572124; http://dx.doi.org/10.1634/theoncologist.2010-0307
- Schlom J, Colcher D, Roselli M, Carrasquillo JA, Reynolds JC, Larson SM, Sugarbaker P, Tuttle SE, Martin EW. Tumor targeting with monoclonal antibody B72.3. Int J Rad Appl Instrum B 1989; 16:137-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2654088; PMID:2654088; http://dx.doi.org/10.1016/0883-2897(89)90184-0
- Katari RS, Fernsten PD, Schlom J. Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas. Cancer Res 1990; 50:4885-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2379152; PMID:2379152
- Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2–6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988; 48:2214-20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2450649; PMID:2450649
- Cao Y, Stosiek P, Springer GF, Karsten U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 1996; 106:197-207. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8877380; PMID:8877380; http://dx.doi.org/10.1007/BF02484401
- Zhang S, Walberg LA, Ogata S, Itzkowitz SH, Koganty RR, Reddish M, Gandhi SS, Longenecker BM, Lloyd KO, Livingston PO. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 1995; 55:3364-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7614472; PMID:7614472
- McCluskie MJ, Weeratna RD, Evans DM, Makinen S, Drane D, Davis HL. CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses. Biomed Res Int 2013; 2013:636847. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23586050; PMID:23586050; http://dx.doi.org/10.1155/2013/636847
- Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22437872; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
- Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010; 9:325-38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20305665; PMID:20305665; http://dx.doi.org/10.1038/nrd3003
- Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008; 26:1774-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18398141; PMID:18398141; http://dx.doi.org/10.1200/JCO.2007.15.7438
- Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, Nicholas ND, Okeley NM, Lyon RP, Benjamin DR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res 2016; 76:2710-9. Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-15-1795; PMID:26921341; http://dx.doi.org/10.1158/0008-5472.CAN-15-1795
- Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, Bordoni RE, Friedberg JW, Sharman JP, Palanca-Wessels MC, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 2015; 126:2798-804. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2015-06-644336; PMID:26377597; http://dx.doi.org/10.1182/blood-2015-06-644336
- Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30:631-7. Available from: http://www.nature.com/doifinder/10.1038/nbt.2289; PMID:22781692; http://dx.doi.org/10.1038/nbt.2289
- Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, et al. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res 2011 [cited 2013 Jan 28]; 71:3352-63. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3085609&tool=pmcentrez&rendertype=abstract; PMID:21505105; http://dx.doi.org/10.1158/0008-5472.CAN-10-4102
- Reuter G, Schauer R, Szeiki C, Kamerling JP, Vliegenthart JF. A detailed study of the periodate oxidation of sialic acids in glycoproteins. Glycoconj J 1989; 6:35-44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2562505; PMID:2562505; http://dx.doi.org/10.1007/BF01047888
- Yin Z, Chowdhury S, McKay C, Baniel C, Wright WS, Bentley P, Kaczanowska K, Gildersleeve JC, Finn MG, BenMohamed L, et al. Significant impact of immunogen design on the diversity of antibodies generated by carbohydrate-based anticancer vaccine. ACS Chem Biol 2015; 10:2364-72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26262839; PMID:26262839; http://dx.doi.org/10.1021/acschembio.5b00406
- Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus Sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. J Cancer 2013; 4:577-84. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3753533&tool=pmcentrez&rendertype=abstract; PMID:23983823; http://dx.doi.org/10.7150/jca.7028
- Reddish M A, Jackson L, Koganty RR, Qiu D, Hong W, Longenecker BM. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes. Glycoconj J 1997; 14:549-60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9298687; PMID:9298687; http://dx.doi.org/10.1023/A:1018576224062
- Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study. Ann Surg 1991; 214:118-24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1867518; PMID:1867518; http://dx.doi.org/10.1097/00000658-199108000-00005
- Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, Mashru R. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release 2016; 226:148-67. Available from: http://linkinghub.elsevier.com/retrieve/pii/S016836591630061X; PMID:26860284; http://dx.doi.org/10.1016/j.jconrel.2016.02.008
- Schlom J, Colcher D, Siler K, Thor A, Bryant G, Johnston WW, Szpak CA, Sugarbaker P, Carrasquillo JA, Reynolds JC. Tumor targeting with monoclonal antibody B72.3: experimental and clinical results. Cancer Treat Res 1990; 51:313-35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1977453; PMID:1977453
- Meredith RF, Khazaeli MB, Macey DJ, Grizzle WE, Mayo M, Schlom J, Russell CD, LoBuglio AF. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999; 5:3254s-3258s. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10541372; PMID:10541372
- Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994; 35:1017-22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8195861; PMID:8195861
- Kim EG, Kim KM. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomol Ther (Seoul) 2015; 23:493-509. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26535074; PMID:26535074; http://dx.doi.org/10.4062/biomolther.2015.116
- Diamantis N, Banerji U. Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer 2016; 114:362-7. Available from: http://dx.doi.org/10.1038/bjc.2015.435; PMID:26742008; http://dx.doi.org/10.1038/bjc.2015.435
- Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. Antibody-drug conjugates: current status and future directions. Drug Discov Today 2014 [cited 2014 Jul 19]; 19:869-81. Available from: http://linkinghub.elsevier.com/retrieve/pii/S135964461300398X; PMID:24239727; http://dx.doi.org/10.1016/j.drudis.2013.11.004
- Yao X, Jiang J, Wang X, Huang C, Li D, Xie K, Xu Q, Li H, Li Z, Lou L, et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat 2015; 153:123-33. Available from: http://link.springer.com/10.1007/s10549-015-3503-3; PMID:26253944; http://dx.doi.org/10.1007/s10549-015-3503-3
- Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015; 4:e985940. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25949870; PMID:25949870; http://dx.doi.org/10.4161/2162402X.2014.985940
- Chen Y, Clark S, Wong T, Chen Y, Chen Y, Dennis MS, Luis E, Zhong F, Bheddah S, Koeppen H, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res 2007; 67:4924-32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17510422; PMID:17510422; http://dx.doi.org/10.1158/0008-5472.CAN-06-4512
- Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, Kitawaki J, Nakanishi H, Narimatsu H, Nakada H. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int J Gynecol Cancer 2012 [cited 2013 Oct 17]; 22:531-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22367369; PMID:22367369; http://dx.doi.org/10.1097/IGC.0b013e3182473292
- Sedlik C, Heitzmann A, Viel S, Ait Sarkouh R, Batisse C, Schmidt F, De La Rochere P, Amzallag N, Osinaga E, Oppezzo P, et al. Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen. Oncoimmunology 2016; 5:e1171434. Available from: http://www.tandfonline.com/doi/full/10.1080/2162402X.2016.1171434; PMID:27622021; http://dx.doi.org/10.1080/2162402X.2016.1171434
- Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al. Engineered CAR T cells targeting the cancer-associated Tn-Glycoform of the membrane Mucin MUC1 control adenocarcinoma. Immunity 2016; 44:1444-54. Available from: http://dx.doi.org/10.1016/j.immuni.2016.05.014; PMID:27332733; http://dx.doi.org/10.1016/j.immuni.2016.05.014
- Osinaga E, Bay S, Tello D, Babino A, Pritsch O, Assemat K, Cantacuzene D, Nakada H, Alzari P. Analysis of the fine specificity of Tn-binding proteins using synthetic glycopeptide epitopes and a biosensor based on surface plasmon resonance spectroscopy. FEBS Lett 2000; 469:24-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10708749; PMID:10708749; http://dx.doi.org/10.1016/S0014-5793(00)01248-5
- Rajpert-De Meyts E, Poll SN, Goukasian I, Jeanneau C, Herlihy AS, Bennett EP, Skakkebaek NE, Clausen H, Giwercman A, Mandel U. Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation. Virchows Arch 2007 [cited 2013 Sep 19]; 451:805-14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17694322; PMID:17694322; http://dx.doi.org/10.1007/s00428-007-0478-4
- Hara S, Yamaguchi M, Takemori Y, Nakamura M, Ohkura Y. Highly sensitive determination of N-acetyl- and N-glycolylneuraminic acids in human serum and urine and rat serum by reversed-phase liquid chromatography with fluorescence detection. J Chromatogr 1986; 377:111-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3711202; PMID:3711202; http://dx.doi.org/10.1016/S0378-4347(00)80766-5
- Yu H, Chokhawala HA, Huang S, Chen X. One-pot three-enzyme chemoenzymatic approach to the synthesis of sialosides containing natural and non-natural functionalities. Nat Protoc 2006; 1:2485-92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17406495; PMID:17406495; http://dx.doi.org/10.1038/nprot.2006.401